Our literature contains honest debate as well as some misinterpreted data 1 regarding revascularization strategies for atherosclerotic aorto-ostial renal artery stenosis. The role for surgical treatment of renal artery stenosis in any patient who can be offered percutaneous therapy is rapidly shrinking. Patients with renal artery stenosis undergoing elective abdominal aortic surgery preferentially receive percutaneous revascularization rather than concomitant surgical revascularization. Procedural morbidity and mortality issues as well as cost considerations have been accepted as favoring percutaneous revascularization over surgical renal revascularization. While a randomized trial would be highly desirable to test these issues, it is unlikely to be done because the results with stent placement are too good and patients will choose to avoid surgery if possible. This was highlighted by the inability to enroll patients in the SCORE trial from the Cleveland Clinic, a study which attempted to randomize renal artery stenosis patients to surgery versus medical therapy. In short, surgeons who wish to continue to perform renal artery revascularization will need to acquire endovascular skills.
The two primary indications for renal artery revascularization are: (1) preservation of renal function and (2) relief of renovascular (renin-dependent) hypertension. Patients with a majority of their viable renal mass jeopardized by a signi®cant renal artery stenosis merit revascularization to preserve renal function. The safety and ef®cacy of renal stent placement for the preservation of renal function has been demonstrated in two separate reports. 2 ,3 The natural history of a renal artery stenosis is to progress or worsen with time. 4 ± 9 Several studies of the natural history of this disease describe progression to occlusion in about 10% of patients being followed. Furthermore, the more severe the stenosis, the more likely it will progress to occlusion. 6 ,1 0 Because occlusion of a renal artery results in the irreversible loss of exocrine kidney function, once an artery has occluded it is often beyond salvage. Therefore, to preserve renal function, we must proactively intervene.
If a patient has well-controlled hypertension on medical therapy with a severe unilateral renal artery stenosis (. 70%) and a normally functioning contralateral kidney, can we convincingly argue that an intervention should be done to`save' the ischemic kidney? Is it true that,`open renal arteries, are better than closed renal arteries'? Can aggressive lipid-lowering therapy`stabilize' renal artery plaque? The answers to these questions lie in the risk/bene®t assessment, and will require carefully performed, randomized trials for a de®nitive answer. In their recent review of the management of renal artery stenosis, Sa®an and Textor 1 1 advocated renal revascularization before the serum creatinine becomes elevated. Progression of an asymptomatic unilateral stenosis to occlusion results in a diminished margin of safety in avoiding renal failure should this patient's normal kidney be injured in the future. 1 1 What about the risks of renal intervention? The likelihood of a successful, uncomplicated renal intervention is very high in several large series with a low risk of major complications, including death, emergency surgery, myocardial infarction, atheroembolization and kidney loss. 1 2 ± 1 4 Given the safety and ef®cacy of percutaneous intervention in a skilled operator's hands, I would choose to have my > 70%`asymptomatic' unilateral renal artery stenosis treated with stent implantation.
Which subgroups of patients with hypertension or renal insuf®ciency should be actively screened for renal artery stenosis? It has become clear that the incidence of renal artery stenosis is much higher in individuals with known or suspected atherosclerotic disease than in the general hypertensive population. 1 5 ,1 6 Patients with known atherosclerosis, such as those with peripheral vascular disease, cerebrovascular disease, or coronary artery disease, and unexplained renal insuf®ciency, unexplained¯ash pulmonary edema, or dif®cult to control hypertension (failure of two or more medications) are at increased risk for renal artery stenosis and, in my opinion, should undergo either non-invasive screening or renal angiography at the time of cardiac catheterization to rule out renal artery stenosis.
Once an appropriate stenosis for revascularization is identi®ed, what is the best method of treatment? The ®elds of interventional radiology and cardiology were done a disservice with the recent publication of a randomized trial of medical therapy versus balloon angioplasty for blood pressure control. 1 This paper demonstrated how methodological aws can invalidate the results of a clinical trial. Speci®cally, the authors allowed almost half of the`medical treatment' group to cross over to the`angioplasty' group whereupon an analysis based upon`intention to treat' led the authors to conclude that there was little if any difference between the treatment groups. Analysis by intention to treat perverted the results of the study and confused many physicians.
The most effective and durable percutaneous method of treatment of aorto-ostial atherosclerotic renal artery stenosis is stent placement. Stents overcome the recoil associated with aorto-ostial lesions that routinely defeats balloon angioplasty. Stents were shown to be dramatically superior to balloon angioplasty in a randomized trial. 1 7 In summary, patients at increased risk for renal artery stenosis should be screened with non-invasive testing or have screening (drive-by) angiography at the time of cardiac catheterization. There is currently not enough data to recommend which asymptomatic patients with renal artery stenosis should undergo revascularization, and therefore it should be left to the wisdom of the clinician and the preference of the patient to individualize therapy. Finally, patients who are candidates for renal artery revascularization due to aorto-ostial, atherosclerotic renal artery stenosis, with uncontrolled blood pressure on medications or renal insuf-®ciency with > 70% of their viable renal mass jeopardized, should preferentially undergo renal artery stent placement.
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